vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and Cartesian Therapeutics, Inc. (RNAC). Click either name above to swap in a different company.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Cartesian Therapeutics is a clinical-stage biopharmaceutical company specializing in RNA-engineered cell therapies for oncology, autoimmune disorders and rare diseases. It operates primarily in the U.S. market, focusing on next-generation CAR-T and immune cell therapies, advancing multiple candidates through mid-stage clinical trials with leading medical research partners.
IVA vs RNAC — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $0 |
| Net Profit | $-49.0M | $-92.6M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -961352.9% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | -802.9% |
| EPS (diluted) | — | $-3.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q4 24 | — | $-836.0K | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $5.1K | $33.3M | ||
| Q1 24 | — | $5.8M | ||
| Q4 23 | — | $8.3M |
| Q4 25 | — | $-92.6M | ||
| Q3 25 | — | $-35.9M | ||
| Q2 25 | — | $15.9M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $-24.2M | ||
| Q2 24 | $-49.0M | $13.8M | ||
| Q1 24 | — | $-56.8M | ||
| Q4 23 | — | $-177.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 3197.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 41.3% | ||
| Q1 24 | — | -228.6% | ||
| Q4 23 | — | -439.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 1226.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | -961352.9% | 41.6% | ||
| Q1 24 | — | -973.0% | ||
| Q4 23 | — | -2149.3% |
| Q4 25 | — | $-3.46 | ||
| Q3 25 | — | $-1.38 | ||
| Q2 25 | — | $0.50 | ||
| Q4 24 | — | $6.60 | ||
| Q3 24 | — | $-1.13 | ||
| Q2 24 | — | $0.54 | ||
| Q1 24 | — | $-10.50 | ||
| Q4 23 | — | $-41.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $125.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-85.4M | $-126.2M |
| Total Assets | $42.6M | $296.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $125.1M | ||
| Q3 25 | — | $143.4M | ||
| Q2 25 | — | $160.3M | ||
| Q4 24 | — | $212.6M | ||
| Q3 24 | — | $219.2M | ||
| Q2 24 | $11.0M | $87.2M | ||
| Q1 24 | — | $103.4M | ||
| Q4 23 | — | $76.9M |
| Q4 25 | — | $-126.2M | ||
| Q3 25 | — | $-35.8M | ||
| Q2 25 | — | $-2.5M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | — | $752.0K | ||
| Q2 24 | $-85.4M | $-101.5M | ||
| Q1 24 | — | $-116.8M | ||
| Q4 23 | — | $-440.2M |
| Q4 25 | — | $296.4M | ||
| Q3 25 | — | $372.7M | ||
| Q2 25 | — | $388.9M | ||
| Q4 24 | — | $435.0M | ||
| Q3 24 | — | $455.3M | ||
| Q2 24 | $42.6M | $347.7M | ||
| Q1 24 | — | $325.2M | ||
| Q4 23 | — | $305.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-17.7M |
| Free Cash FlowOCF − Capex | — | $-18.2M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-62.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-17.7M | ||
| Q3 25 | — | $-15.6M | ||
| Q2 25 | — | $-17.5M | ||
| Q4 24 | — | $-7.0M | ||
| Q3 24 | — | $13.7M | ||
| Q2 24 | — | $-14.4M | ||
| Q1 24 | — | $-15.9M | ||
| Q4 23 | — | $-23.3M |
| Q4 25 | — | $-18.2M | ||
| Q3 25 | — | $-16.9M | ||
| Q2 25 | — | $-20.1M | ||
| Q4 24 | — | $-7.7M | ||
| Q3 24 | — | $7.5M | ||
| Q2 24 | — | $-16.0M | ||
| Q1 24 | — | $-16.5M | ||
| Q4 23 | — | $-23.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 921.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -48.2% | ||
| Q1 24 | — | -282.9% | ||
| Q4 23 | — | -282.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | -84.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 10.3% | ||
| Q4 23 | — | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.10× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.04× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
